Type 2 Diabetes Management

Initial Treatment

The American Diabetes Association recommends starting metformin 500 mg daily with lifestyle modifications immediately at diagnosis unless specific contraindications exist 1, 2
Metformin is first-line therapy, providing glycemic control with minimal hypoglycemia risk and potential weight benefits, as per American Diabetes Association and American College of Cardiology guidelines 3, 1

For metabolically stable patients, the American College of Cardiology recommends metformin 500 mg PO daily with dinner, increasing by 500 mg every 1-2 weeks as tolerated, with a target dose of 2000 mg daily in divided doses 2, 1
For patients with severe hyperglycemia without ketoacidosis, the American Diabetes Association recommends insulin glargine 0.5 units/kg subcutaneously once daily at bedtime, plus metformin 500 mg PO daily 4, 1, 2
For patients with diabetic ketoacidosis or marked ketosis, the American Diabetes Association recommends intravenous insulin infusion per DKA protocol until acidosis resolves, then transitioning to subcutaneous insulin, with metformin 500 mg PO daily added after ketosis resolution 4, 1

For patients with cardiovascular disease or heart failure, the American College of Cardiology recommends metformin 500 mg PO daily, plus empagliflozin 10 mg PO daily, or a GLP-1 RA such as semaglutide 0.25 mg subcutaneously weekly, titrated to 0.5-1.0 mg weekly 3
For patients with chronic kidney disease, the American Diabetes Association recommends metformin if eGFR >30 mL/min/1.73 m², plus empagliflozin 10 mg PO daily, or canagliflozin 100 mg PO daily 3
For pediatric/adolescent patients, the American Academy of Pediatrics recommends metformin 500 mg PO daily with dinner, titrated to maximum 2000 mg daily in divided doses, with emphasis on family-centered lifestyle modifications 6, 5, 4

The American Diabetes Association recommends A1C every 3 months until target achieved, then every 6 months, with a target A1C <7% for most adults, and <6.5% for selected individuals if achievable without hypoglycemia 1, 2
The American College of Cardiology recommends individualizing glycemic targets based on life expectancy, comorbidities, hypoglycemia risk, and patient preferences 3